Timing of Endoscopy in Cirrhotic Patients With Acute Variceal Bleeding : Timing of Endoscopy in Cirrhotic Patients With Acute Variceal Bleeding
A total of 368 cirrhotic patients presenting with AUGIB that is highly suspected to be from AVB will be enrolled. They will be stratified according to the severity of liver function and hemodynamic status at admission, and randomly assigned at a 1:1 ratio into early (within 12 hours after admission) and delayed (within 12-24 hours after admission) endoscopy groups within each stratum. The primary outcomes include the rates of 5-day failure to control bleeding after admission and 6-week rebleeding. The secondary outcomes include 6-week mortality and incidence of adverse events..
Medienart: |
Klinische Studie |
---|
Erscheinungsjahr: |
2024 |
---|---|
Erschienen: |
2024 |
Enthalten in: |
ClinicalTrials.gov - (2024) vom: 26. März Zur Gesamtaufnahme - year:2024 |
---|
Sprache: |
Englisch |
---|
Links: |
Volltext [kostenfrei] |
---|
Themen: |
610 |
---|
Anmerkungen: |
Source: Link to the current ClinicalTrials.gov record., First posted: September 11, 2023, Last downloaded: ClinicalTrials.gov processed this data on April 03, 2024, Last updated: April 03, 2024 |
---|
fisyears: |
|
---|---|
Förderinstitution / Projekttitel: |
|
PPN (Katalog-ID): |
CTG00016187X |
---|
LEADER | 01000caa a22002652 4500 | ||
---|---|---|---|
001 | CTG00016187X | ||
003 | DE-627 | ||
005 | 20240403010433.0 | ||
007 | cr uuu---uuuuu | ||
008 | 240327s2024 xx |||||o 00| ||eng c | ||
035 | |a (DE-627)CTG00016187X | ||
035 | |a (UBBS_Klinische_Studien)NCT06031402 | ||
035 | |a (UBBS_Klinische_Studien)XHNKKY-ENDO-AVB | ||
040 | |a DE-627 |b ger |c DE-627 |e rakwb | ||
041 | |a eng | ||
245 | 1 | 0 | |a Timing of Endoscopy in Cirrhotic Patients With Acute Variceal Bleeding |b Timing of Endoscopy in Cirrhotic Patients With Acute Variceal Bleeding |
264 | 1 | |c 2024 | |
336 | |a Text |b txt |2 rdacontent | ||
337 | |a Computermedien |b c |2 rdamedia | ||
338 | |a Online-Ressource |b cr |2 rdacarrier | ||
500 | |a Source: Link to the current ClinicalTrials.gov record., First posted: September 11, 2023, Last downloaded: ClinicalTrials.gov processed this data on April 03, 2024, Last updated: April 03, 2024 | ||
520 | |a A total of 368 cirrhotic patients presenting with AUGIB that is highly suspected to be from AVB will be enrolled. They will be stratified according to the severity of liver function and hemodynamic status at admission, and randomly assigned at a 1:1 ratio into early (within 12 hours after admission) and delayed (within 12-24 hours after admission) endoscopy groups within each stratum. The primary outcomes include the rates of 5-day failure to control bleeding after admission and 6-week rebleeding. The secondary outcomes include 6-week mortality and incidence of adverse events. | ||
650 | 2 | |a Gastrointestinal Hemorrhage | |
650 | 2 | |a Hemorrhage | |
650 | 4 | |a Study Type: Interventional | |
650 | 4 | |a Recruitment Status: Not yet recruiting | |
650 | 4 | |a 610 | |
773 | 0 | 8 | |i Enthalten in |t ClinicalTrials.gov |g (2024) vom: 26. März |
773 | 1 | 8 | |g year:2024 |g day:26 |g month:03 |
856 | 4 | 0 | |u https://clinicaltrials.gov/show/NCT06031402 |z kostenfrei |3 Volltext |
912 | |a GBV_CTG | ||
951 | |a AR | ||
952 | |j 2024 |b 26 |c 03 |